Financiere des Professionnels Fonds d investissement inc. Trims Stock Position in Johnson & Johnson $JNJ

Financiere des Professionnels Fonds d investissement inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 19.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 46,180 shares of the company's stock after selling 11,024 shares during the quarter. Johnson & Johnson comprises approximately 0.7% of Financiere des Professionnels Fonds d investissement inc.'s investment portfolio, making the stock its 29th biggest position. Financiere des Professionnels Fonds d investissement inc.'s holdings in Johnson & Johnson were worth $11,288,000 as of its most recent SEC filing. Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Blueline Advisors LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $25,000. Cresta Advisors Ltd. acquired a new position in Johnson & Johnson during the 4th quarter worth $26,000. DecisionPoint Financial LLC increased its holdings in Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock worth $30,000 after purchasing an additional 75 shares during the period. Bay Harbor Wealth Management LLC increased its holdings in Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock worth $31,000 after purchasing an additional 49 shares during the period. Finally, Family CFO Inc acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $31,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors. In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company's stock. Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance.